Abstract

Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients

Rheumatology (Oxford). 2021 Nov 3;60(11):5233-5238.doi: 10.1093/rheumatology/keab193.

Ioana A Onac 1, Benjamin D Clarke 1, Cristina Tacu 2, Mark Lloyd 3, Vijay Hajela 2, Thomas Batty 2, Jamie Thoroughgood 4, Sandra Smith 3, Hannah Irvine 5, Diane Hill 6, Grace Baxter 7, Natalie Horwood 7, Suma Mahendrakar 7, Rizwan Rajak 7, Sian Griffith 4, Patrick D W Kiely 6 8, James Galloway 9

 
     

Author information

  • 1Department of Academic Rheumatology, King's College London, London.
  • 2Department of Rheumatology, Brighton and Sussex University Hospital, Brighton.
  • 3Department of Rheumatology, Frimley Park Hospital, Frimley.
  • 4Department of Rheumatology, East Surrey Hospital, Redhill.
  • 5Department of Rheumatology, Royal Berkshire NHS Foundation Trust, Reading.
  • 6Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London.
  • 7Department of Rheumatology, Croydon University Hospital, Croydon.
  • 8Institute of Medical and Biomedical Education, University of London St George's.
  • 9Centre for Rheumatic Diseases, King's College London, London, UK.

Abstract

Objective: Real-world secukinumab gastrointestinal-related adverse events (GIRAE) data during treatment for AS and PsA are lacking. We aimed to obtain this through baseline evaluation of pre-existing IBD rates and predictors of GIRAE.

Methods: Patient electronic and paper records commencing secukinumab from 10 UK hospitals between 2016 and 2019 were reviewed. GIRAE after initiation were defined as: definite [objective evidence of IBD (biopsy proven), clear temporal association, resolution of symptoms on drug withdrawal, no alternative explanation felt more likely], probable (as per definite, but without biopsy confirmation) or possible (gastrointestinal symptoms not fulfilling definite or probable criteria).

Results: Data for all 306 patients started on secukinumab were analysed: 124 (40.5%) AS and 182 (59.5%) PsA. Twenty-four of 306 (7.8%) experienced GIRAE after starting secukinumab. Amongst patients who developed GIRAE, four (1.3%) had definite, seven (2.3%) probable and 13 (4.2%) possible IBD. All definite cases were patients with AS and stopped secukinumab; two had pre-existing IBD and two (0.7%) were de novo cases of which one required surgical intervention. Seven patients (2.3%) had pre-existing diagnoses of IBD prior to initiation, of which five patients experienced GIRAE.

Conclusion: Absolute rates of new IBD in patients starting secukinumab are low. The majority of patients developing new GIRAE did not develop objective evidence of IBD or stop therapy. For patients with pre-existing IBD and AS the risk of GIRAE is much higher, and prescribing alternatives should be considered.

 

 

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.